The active ingredient of Diabrezide is gliclazide, a sulfonylurea derivative.

Gliclazide, like other sulfonylurea derivatives, lowers blood glucose levels in both healthy volunteers and patients with type 2 diabetes mellitus (non-insulin-dependent). This occurs by increasing insufficient insulin secretion and reducing peripheral insulin resistance.

Diabrezide is available in packs of 40 tablets, with each tablet containing 80 mg of gliclazide. Diabrezide is the first gliclazide-based preparation that features a hydrophilic matrix, which facilitates the absorption of the active substance. The preparation ensures high bioavailability of the drug, leading to higher plasma levels of gliclazide and, consequently, better metabolic control for the patient.

Diabrezide is a short-acting drug, in line with recommendations for the treatment of type 2 diabetes, especially in elderly patients (e.g., UKPDS).

Diabrezide is included in the list of reimbursable drugs for diabetes treatment with a fixed cost (RYCZAŁT)*.

Diabrezide is also included in the list of free medications for seniors over 65.
* According to the decree of the Minister of Health regarding the list of reimbursable drugs, foods for special medical purposes, and medical devices, effective from April 1, 2024.